Akums Drugs and Pharmaceuticals Recommends Dividend Following Board Review of Financial Results

Akums Drugs and Pharmaceuticals Recommends Dividend Following Board Review of Financial Results​

Akums Drugs and Pharmaceuticals Limited announced key corporate decisions following its Board meeting held on May 14, 2026. The Board approved the financial results for the year ended March 31, 2026, and recommended dividends, alongside appointing new auditors and senior management personnel.

Dividend Recommendation​

At the Board meeting, the directors reviewed the Un-audited (Standalone & Consolidated) Financial Results for the quarter ended March 31, 2026, and the Audited Financial Results for the year ended March 31, 2026.

The Board of Directors recommended:

• Final Dividend: Rs. 1.00 per equity share (50% of face value of Rs. 2).
• Special Dividend: Rs. 2.00 per equity share (100% of face value of Rs. 2).

These dividends are subject to the approval of the Company's shareholders at the upcoming Annual General Meeting (AGM). The Board also fixed Friday, July 03, 2026, as the record date to ascertain the eligibility of shareholders for the dividend payment. The AGM is scheduled for Friday, July 10, 2026.

Financial Performance Highlights (Consolidated)​

The consolidated financial results for the year ended March 31, 2026, showed a significant performance overview compared to the previous year.

The following tables summarize the key financial results and the balance sheet positions for the year ended March 31, 2026.

Consolidated Statement of Profit and Loss (Amounts in million, unless otherwise stated)


Consolidated Balance Sheet (Amounts in million, unless otherwise stated)

Governance and Operational Updates​

The Board meeting also addressed governance and operational appointments:

• Auditors: The directors recommended the re-appointment of M/s. Balwinder & Associates, Cost Accountants, as Cost Auditors for the Financial Year 2026-27, with a remuneration of Rs. 3,00,000/-. Additionally, Mahajan & Aibara LLP, Chartered Accountants, were appointed as Internal Auditors for the same period.
• Management Change: The Board approved the appointment of Mr. V Jagannathan as Senior Management Personnel, President - HR. Concurrently, Mr. Arvind Srivastava ceased his role as Senior Management Personnel, President - HR, effective May 14, 2026.

Material Observations from Auditors​

The independent audit reports highlighted a significant matter regarding corporate compliance and legal proceedings. Auditors drew attention to a search and seizure operation conducted by the Income Tax Department during the financial year ended March 31, 2025, at the offices and units of the Holding Company and its subsidiaries.

The Group has been involved in ongoing block assessment proceedings under Section 158BC of the Income Tax Act, 1961. As of the reporting date, the management stated that no material adjustments were required to the standalone or consolidated financial results for the quarter and year ended March 31, 2026, despite the ongoing nature of the proceedings.

Divisional Revenue (Consolidated)​

The Group operates across five segments, including Contract Development and Manufacturing operations (CDMO), Active Pharmaceutical Ingredient (API), Domestic Branded Formulations, International Branded Formulations, and Trade Generics.

Revenue from operations for the Group reached 11,578.68 million for the quarter ended March 31, 2026, up from 10,555.47 million in the same period last year. The total annual revenue from operations for the year ended March 31, 2026, was 43,590.17 million.

AKUMS Stock Price Movement​

As of 2:51 PM, shares of Akums Drugs and Pharmaceuticals Limited are slipping by 2.73% in live trading, currently trading at ₹525.6. The stock moved on significant interest, handling a total volume of 622,794 shares during the current market session.